Literature DB >> 23430616

Inactivation of nuclear factor-Y inhibits vascular smooth muscle cell proliferation and neointima formation.

Carlos Silvestre-Roig1, Patricia Fernández, Vanesa Esteban, Óscar M Pello, Ciro Indolfi, Cristina Rodríguez, Ricardo Rodríguez-Calvo, María Dolores López-Maderuelo, Gerhard Bauriedel, Randolph Hutter, Valentín Fuster, Borja Ibáñez, Juan M Redondo, José Martínez-González, Vicente Andrés.   

Abstract

OBJECTIVE: Atherosclerosis and restenosis are multifactorial diseases associated with abnormal vascular smooth muscle cell (VSMC) proliferation. Nuclear factor-Y (NF-Y) plays a major role in transcriptional activation of the CYCLIN B1 gene (CCNB1), a key positive regulator of cell proliferation and neointimal thickening. Here, we investigated the role of NF-Y in occlusive vascular disease. APPROACH AND
RESULTS: We performed molecular and expression studies in cultured cells, animal models, and human tissues. We find upregulation of NF-Y and cyclin B1 expression in proliferative regions of murine atherosclerotic plaques and mechanically induced lesions, which correlates with higher binding of NF-Y to target sequences in the CCNB1 promoter. NF-YA expression in neointimal lesions is detected in VSMCs, macrophages, and endothelial cells. Platelet-derived growth factor-BB, a main inductor of VSMC growth and neointima development, induces the recruitment of NF-Y to the CCNB1 promoter and augments both CCNB1 mRNA expression and cell proliferation through extracellular signal-regulated kinase 1/2 and Akt activation in rat and human VSMCs. Moreover, adenovirus-mediated overexpression of a NF-YA-dominant negative mutant inhibits platelet-derived growth factor-BB-induced CCNB1 expression and VSMC proliferation in vitro and neointimal lesion formation in a mouse model of femoral artery injury. We also detect NF-Y expression and DNA-binding activity in human neointimal lesions.
CONCLUSIONS: Our results identify NF-Y as a key downstream effector of the platelet-derived growth factor-BB-dependent mitogenic pathway that is activated in experimental and human vasculoproliferative diseases. They also identify NF-Y inhibition as a novel and attractive strategy for the local treatment of neointimal formation induced by vessel denudation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23430616     DOI: 10.1161/ATVBAHA.112.300580

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  3 in total

1.  Single-Cell Epigenomics and Functional Fine-Mapping of Atherosclerosis GWAS Loci.

Authors:  Kadri Õunap; Lindsey K Stolze; Redouane Aherrahrou; Tiit Örd; Valtteri Nurminen; Anu Toropainen; Ilakya Selvarajan; Tapio Lönnberg; Einari Aavik; Seppo Ylä-Herttuala; Mete Civelek; Casey E Romanoski; Minna U Kaikkonen
Journal:  Circ Res       Date:  2021-05-24       Impact factor: 17.367

2.  Metabolic Syndrome Mediates ROS-miR-193b-NFYA-Dependent Downregulation of Soluble Guanylate Cyclase and Contributes to Exercise-Induced Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction.

Authors:  Taijyu Satoh; Longfei Wang; Cristina Espinosa-Diez; Bing Wang; Scott A Hahn; Kentaro Noda; Elizabeth R Rochon; Matthew R Dent; Andrea R Levine; Jeffrey J Baust; Samuel Wyman; Yijen L Wu; Georgios A Triantafyllou; Ying Tang; Mike Reynolds; Sruti Shiva; Cynthia St Hilaire; Delphine Gomez; Dmitry A Goncharov; Elena A Goncharova; Stephen Y Chan; Adam C Straub; Yen-Chun Lai; Charles F McTiernan; Mark T Gladwin
Journal:  Circulation       Date:  2021-06-23       Impact factor: 39.918

3.  The Coronary Artery Disease-associated Coding Variant in Zinc Finger C3HC-type Containing 1 (ZC3HC1) Affects Cell Cycle Regulation.

Authors:  Peter D Jones; Michael A Kaiser; Maryam Ghaderi Najafabadi; David G McVey; Allan J Beveridge; Christine L Schofield; Nilesh J Samani; Tom R Webb
Journal:  J Biol Chem       Date:  2016-05-19       Impact factor: 5.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.